Next Science Ltd NXSCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.25
- Day Range
- $0.26–0.26
- 52-Week Range
- $0.12–0.51
- Bid/Ask
- $0.23 / $0.31
- Market Cap
- $75.84 Mil
- Volume/Avg
- 10,000 / 10,030
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.64
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- —
- Website
- https://www.nextscience.com
Comparables
Valuation
|
Metric
|
NXSCF
|
SLX
|
AZT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 56.43 |
Price/Book Value | 5.69 | 8.08 | 4.31 |
Price/Sales | 2.64 | 212.37 | 11.23 |
Price/Cash Flow | — | 1,208.99 | 39.45 |
Price/Earnings
NXSCF
SLX
AZT
Financial Strength
|
Metric
|
NXSCF
|
SLX
|
AZT
|
|---|---|---|---|
Quick Ratio | 3.35 | 22.79 | 13.42 |
Current Ratio | 3.64 | 22.98 | 14.08 |
Interest Coverage | −20.34 | −528.05 | — |
Quick Ratio
NXSCF
SLX
AZT
Profitability
|
Metric
|
NXSCF
|
SLX
|
AZT
|
|---|---|---|---|
Return on Assets (Normalized) | −114.40% | −16.19% | 6.33% |
Return on Equity (Normalized) | −231.91% | −16.89% | 7.00% |
Return on Invested Capital (Normalized) | −155.12% | −21.33% | 5.41% |
Return on Assets
NXSCF
SLX
AZT
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Xnshzrkfnv | Kqnt | $70.0 Bil | |
MKKGY
| Merck KGaA ADR | Zdrfpyvbxw | Klklqn | $68.1 Bil | |
HLN
| Haleon PLC ADR | Gjplxtwly | Wjfn | $36.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Rwwggbvn | Qztg | $14.3 Bil | |
VTRS
| Viatris Inc | Gnmlrkl | Snq | $13.2 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Mngwlxxjy | Jhzv | $11.9 Bil | |
CTLT
| Catalent Inc | Pytsglp | Dlddyzn | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Crxnglpy | Cdgyx | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Rksbzkmy | Jys | $3.7 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Mwycvbv | Ngbpt | $3.4 Bil |